Swedes develop Huntington's medicine
A Swedish biotechnology firm has developed a new medicine which provides hope for sufferers of Huntington's disease, according to a report in Göteborgs-Posten.
The new medicine, based on the findings of Nobel prize winning scientist Arvid Carlsson, is set to replace the only other treatment for the disease.
Huntexil is the name given to the new medicine which has been found to relieve the disease's tension and tremors without the secondary side-effects of existing drugs.
The next stage in the development of Huntexil is to have it approved as a medicine with its prospects to date reported to be bright.
The company responsible for the research is called Neurosearch, a Denmark-based firm with a subsidiary in Gothenburg. The firm emerged from the group of research scientists working with Arvid Carlsson.
Arvid Carlsson is a Swedish scientist who is best known for his work to develop a method for measuring the amount of dopamine in brain tissues and it effects on Parkinson's disease.
Carlsson was awarded the Nobel prize in Physiology or Medicine in 2000.
Comments
See Also
The new medicine, based on the findings of Nobel prize winning scientist Arvid Carlsson, is set to replace the only other treatment for the disease.
Huntexil is the name given to the new medicine which has been found to relieve the disease's tension and tremors without the secondary side-effects of existing drugs.
The next stage in the development of Huntexil is to have it approved as a medicine with its prospects to date reported to be bright.
The company responsible for the research is called Neurosearch, a Denmark-based firm with a subsidiary in Gothenburg. The firm emerged from the group of research scientists working with Arvid Carlsson.
Arvid Carlsson is a Swedish scientist who is best known for his work to develop a method for measuring the amount of dopamine in brain tissues and it effects on Parkinson's disease.
Carlsson was awarded the Nobel prize in Physiology or Medicine in 2000.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.